RONALD REAGAN UCLA
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $250.6M
- Transactions
- 15,121
- Companies
- 40
- Average per transaction
- $16,576
Who reported the payments
| Merck | $44,982,531 |
| Novartis | $14,967,704 |
| AstraZeneca | $13,584,066 |
| Amgen | $12,535,052 |
| Genentech, Inc. | $12,061,749 |
| AbbVie | $10,818,092 |
| Daiichi Sankyo Inc. | $8,650,103 |
| Eli Lilly | $6,148,843 |
| Sarepta Therapeutics, Inc. | $5,961,397 |
| E.r. Squibb & Sons, L.L.C. | $4,969,095 |
| Siemens Medical Solutions USA, Inc. | $4,756,381 |
| Regeneron | $4,329,362 |
| Gilead | $4,013,329 |
| Janssen Research & Development, LLC | $3,580,410 |
| Biogen | $3,468,619 |
| Bristol Myers Squibb | $3,428,749 |
| Servier Bioinnovation | $3,316,322 |
| CSL Behring | $3,310,661 |
| PTC Therapeutics, Inc. | $3,174,896 |
| Sanofi US Services Inc. | $2,464,613 |
| Beigene, Ltd. | $2,416,168 |
| Jazz Pharmaceuticals Inc. | $2,361,315 |
| Abbott | $2,236,537 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,086,933 |
| Servier Pharmaceuticals LLC | $2,053,552 |
| Astrazeneca UK Limited | $2,001,399 |
| Boston Scientific | $1,970,846 |
| Boehringer Ingelheim | $1,911,892 |
| Pfizer | $1,896,474 |
| Biomerieux Inc | $1,753,557 |
| Seagen Inc. | $1,670,480 |
| United Therapeutics Corporation | $1,567,742 |
| Deciphera Pharmaceuticals Inc. | $1,559,020 |
| Alkermes, Inc. | $1,497,059 |
| Astellas Pharma Global Development | $1,389,700 |
| Incyte Corporation | $1,364,940 |
| EMD Serono, Inc. | $1,333,792 |
| Agios Pharmaceuticals, Inc. | $1,306,102 |
| Astellas US Technologies | $1,118,150 |
| BD | $1,046,745 |